We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





Low-Cost COVID-19 Testing Platform Combines Sensitivity of PCR and Speed of Antigen Tests

By LabMedica International staff writers
Posted on 27 Sep 2022

DNA is best known for its genetic properties, but it also can be folded into custom nanoscale structures that can perform functions or specifically bind to other structures much like proteins do. More...

Now, a new study has shown that tiny nets woven from DNA strands can ensnare the spike protein of the SARS-CoV-2 virus that causes COVID-19, lighting up the virus for a fast-yet-sensitive diagnostic test – and also impeding it from infecting cells, thus opening a new possible route to antiviral treatment.

The DNA nets’ ability to detect and impede COVID-19 in human cell cultures was demonstrated by researchers at the University of Illinois at Urbana-Champaign (Champaign, IL, USA). The DNA nets were designed to bind to the coronavirus spike protein – the structure that sticks out from the surface of the virus and binds to receptors on human cells to infect them. Once bound, the nets give off a fluorescent signal that can be read by an inexpensive handheld device in about 10 minutes. The researchers demonstrated that their DNA nets effectively targeted the spike protein and were able to detect the virus at very low levels, equivalent to the sensitivity of gold-standard PCR tests that detect the virus’s genetic material but can take a day or more to return results from a clinical lab.

The technique holds several advantages. It does not need any special preparation or equipment, and can be performed at room temperature, so all a user would do is mix the sample with the solution and read it. The researchers estimated in their study that the method would cost USD 1.26 per test. The technique can detect the entire virus, which is still infectious, and distinguish it from fragments that may not be infectious anymore. This not only gives patients and physicians a better understanding of whether they are infectious, but it could greatly improve community-level modeling and tracking of active outbreaks, such as through wastewater. In addition, the DNA nets inhibited the virus’s spread in live cell cultures, with the antiviral activity increasing with the size of the DNA net scaffold. This points to DNA structures’ potential as therapeutic agents. The DNA net platform can be adapted to other viruses and even multiplexed so that a single test could detect multiple viruses.

“This platform combines the sensitivity of clinical PCR tests and the speed and low cost of antigen tests,” said study leader Xing Wang, a professor of bioengineering and of chemistry at Illinois. “We need tests like this for a couple of reasons. One is to prepare for the next pandemic. The other reason is to track ongoing viral epidemics – not only coronaviruses, but also other deadly and economically impactful viruses like HIV or influenza.”

Related Links:
University of Illinois at Urbana-Champaign 


Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
Serological Pipet Controller
PIPETBOY GENIUS
New
Hepatitis A Rapid Test
Anti-HAV IgM Rapid Test Kit
New
Plasmodium Test
Plasmodium DNA Real Time PCR Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Pathology

view channel
Image: Microscopy image of invasive breast cancer cells degrading their underlying extracellular matrix (Photo courtesy of University of Turku)

Visualization Tool Illuminates Breast Cancer Cell Migration to Suggest New Treatment Avenues

Patients with breast cancer who progress from ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC) face a significantly worse prognosis, as metastatic disease remains incurable.... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.